Glenmark Pharmaceuticals will be presenting new and updated data on GBR 830 at the upcoming International Investigative Dermatology (IID) meeting in Orlando, Florida.
The GBR 830 presentations at IID 2018 include one oral presentation and three poster presentations on GBR 830, an investigational treatment for moderate-to-severe atopic dermatitis. The IID meeting occurs only once every five years and brings together top researchers from across the globe to further the understanding of skin biology and dermatologic disease.
Glenmark Pharmaceuticals is a global innovative pharmaceutical company with operations in more than 50 countries.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: